Filings & corporate actions
72 results filed
CSVNext results · Q2 FY27
Expected 17 Oct 2026 – 7 Nov 2026
Estimate: filed 17–38 days after quarter end, last 5 times
Dividend
₹24.00 per share · last 9 Jul 2026
2026
- 28 JulresultsResults · Q1 FY27 · consolidated and standalone-1.3%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026+5.5%NSE
- 9 JuldividendDividend · ₹24.00 per share+8.3%
- 29 AprresultsResults · Q4 FY26 · consolidated and standalone+13.0%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026-0.5%NSE
- 27 JanresultsResults · Q3 FY26 · consolidated and standalone-6.7%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-2.9%NSE
Reaction to results · all yearsrose on day 0 in 30 of 72 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 28 Jul 2026 | -1.3% | -6.3% | -10.2% | 1.2× |
| Q4 FY26 | 29 Apr 2026 | +13.0% | +21.3% | +7.0% | 110.8× |
| Q3 FY26 | 27 Jan 2026 | -6.7% | -5.9% | -10.5% | 31.4× |
| Q2 FY26 | 17 Oct 2025 | +5.4% | +4.4% | -1.1% | 18.8× |
| Q1 FY26 | 25 Jul 2025 | -9.9% | -5.7% | -7.6% | 4.3× |
| Q4 FY25 | 29 Apr 2025 | +2.8% | -4.4% | +2.1% | 31.3× |
| Q3 FY25 | 24 Jan 2025 | +9.0% | +18.3% | +13.7% | 21.9× |
| Q2 FY25 | 7 Nov 2024 | -6.2% | -21.1% | -12.7% | 2.3× |
| Q1 FY25 | 19 Jul 2024 | +3.0% | +3.3% | +17.5% | 9.5× |
| Q4 FY24 | 30 Apr 2024 | -2.5% | -6.2% | -7.3% | 5.3× |
| Q3 FY24 | 1 Feb 2024 | +2.6% | +0.5% | -5.1% | 2.7× |
| Q2 FY24 | 19 Oct 2023 | +1.3% | -3.6% | +4.8% | 2.9× |
| Q1 FY24 | 28 Jul 2023 | +3.6% | +12.3% | +19.5% | 3.2× |
| Q4 FY23 | 28 Apr 2023 | -4.8% | -7.3% | -9.3% | 2.1× |
| Q3 FY23 | 2 Feb 2023 | +1.9% | +7.7% | +7.0% | 1.8× |
| Q2 FY23 | 18 Oct 2022 | +1.6% | +3.6% | +12.9% | 1.5× |
| Q4 FY22 | 29 Apr 2022 | -9.7% | -17.0% | -13.6% | 4.3× |
| Q3 FY22 | 25 Jan 2022 | -4.8% | -4.9% | -22.5% | 1.3× |
| Q2 FY22 | 29 Oct 2021 | +13.9% | +11.1% | -4.9% | 6.9× |
| Q1 FY22 | 28 Jul 2021 | +4.9% | +3.5% | +3.5% | 9.1× |
| Q4 FY21 | 30 Apr 2021 | -3.6% | -6.8% | -8.7% | 0.9× |
| Q3 FY21 | 25 Jan 2021 | -1.6% | -1.0% | -1.6% | 2.1× |
| Q2 FY21 | 30 Oct 2020 | -0.5% | +5.2% | +5.0% | 1.5× |
| Q1 FY21 | 31 Jul 2020 | +12.5% | +23.6% | +2.1% | 5.8× |
| Q4 FY20 | 5 Jun 2020 | -2.6% | -7.1% | -6.0% | 3.1× |
| Q3 FY20 | 31 Jan 2020 | -8.4% | -9.8% | -24.8% | 0.5× |
| Q2 FY20 | 31 Oct 2019 | +20.0% | +37.2% | +26.9% | 6.5× |
| Q1 FY20 | 31 Jul 2019 | -7.3% | -13.9% | -20.0% | 3.4× |
| Q4 FY19 | 7 May 2019 | +0.3% | -0.2% | +10.1% | 0.5× |
| Q3 FY19 | 1 Mar 2019 | +2.6% | +7.7% | +3.9% | 1.8× |
| Q2 FY19 | 20 Nov 2018 | +0.9% | -5.2% | +2.6% | 0.5× |
| Q1 FY19 | 7 Aug 2018 | -0.8% | -3.7% | +21.4% | 0.3× |
| Q4 FY18 | 26 May 2018 | +0.6% | -3.6% | +2.3% | 0.7× |
| Q3 FY18 | 9 Feb 2018 | -0.4% | +5.4% | -1.8% | 0.2× |
| Q2 FY18 | 21 Nov 2017 | -0.5% | +11.9% | +22.9% | 1.0× |
| Q1 FY18 | 8 Aug 2017 | -0.7% | +1.6% | +7.1% | 2.1× |
| Q4 FY17 | 27 May 2017 | +1.7% | +8.9% | +1.0% | 0.6× |
| Q3 FY17 | 2 Feb 2017 | +1.8% | -2.2% | +0.1% | 0.5× |
| Q2 FY17 | 26 Oct 2016 | +1.1% | -1.7% | -6.3% | 0.7× |
| Q1 FY17 | 6 Aug 2016 | -0.3% | +6.4% | +13.0% | 0.3× |
| Q4 FY16 | 4 May 2016 | -2.9% | -3.5% | +3.0% | 0.1× |
| Q3 FY16 | 9 Feb 2016 | -6.2% | -12.1% | +0.3% | 0.7× |
| Q2 FY16 | 30 Oct 2015 | -1.4% | -2.1% | +67.2% | 0.3× |
| Q1 FY16 | 28 Jul 2015 | -6.5% | -8.3% | -24.0% | 1.1× |
| Q4 FY15 | 30 Apr 2015 | +10.0% | +2.4% | +8.7% | 1.6× |
| Q3 FY15 | 23 Jan 2015 | 0.0% | +4.7% | +17.7% | 1.8× |
| Q2 FY15 | 22 Oct 2014 | -5.3% | -9.1% | -11.8% | 0.9× |
| Q1 FY15 | 24 Jul 2014 | -4.4% | -8.6% | -5.8% | 0.2× |
| Q4 FY14 | 5 May 2014 | -0.5% | -2.2% | +10.3% | 0.6× |
| Q3 FY14 | 7 Feb 2014 | +2.9% | +12.4% | +21.8% | 0.4× |
| Q2 FY14 | 21 Oct 2013 | 0.0% | +4.6% | -0.5% | 0.3× |
| Q1 FY14 | 29 Jul 2013 | -5.3% | -12.1% | -14.0% | 0.8× |
| Q4 FY13 | 9 May 2013 | -7.7% | -6.0% | -7.0% | 5.5× |
| Q3 FY13 | 7 Feb 2013 | -2.9% | -13.7% | -25.8% | 0.9× |
| Q2 FY13 | 23 Oct 2012 | -1.3% | -3.0% | -1.1% | 0.9× |
| Q1 FY13 | 10 Aug 2012 | 0.0% | +4.5% | +7.0% | 0.1× |
| Q4 FY12 | 3 May 2012 | -0.5% | -9.8% | -8.0% | 0.7× |
| Q3 FY12 | 23 Jan 2012 | -1.8% | -5.5% | -4.3% | 0.2× |
| Q2 FY12 | 19 Oct 2011 | +0.3% | -2.4% | -13.9% | 1.7× |
| Q1 FY12 | 28 Jul 2011 | -0.3% | -0.4% | -1.9% | 0.1× |
| Q4 FY11 | 28 Apr 2011 | +0.6% | -3.8% | +2.8% | 2.5× |
| Q3 FY11 | 17 Jan 2011 | -4.6% | -2.5% | -6.0% | 2.0× |
| Q2 FY11 | 20 Oct 2010 | -3.4% | -0.7% | -7.2% | 0.7× |
| Q1 FY11 | 29 Jul 2010 | -1.6% | +1.0% | +4.7% | 0.5× |
| Q4 FY10 | 12 May 2010 | +1.8% | +0.1% | +0.4% | 5.5× |
| Q3 FY10 | 19 Jan 2010 | -3.4% | -17.4% | -14.0% | 1.0× |
| Q2 FY10 | 28 Oct 2009 | +1.4% | +4.0% | +1.3% | 0.6× |
| Q1 FY10 | 29 Jul 2009 | +3.1% | +1.9% | +16.0% | 4.1× |
| Q4 FY09 | 25 Jun 2009 | +4.8% | -2.2% | +4.7% | 0.7× |
| Q3 FY09 | 29 Jan 2009 | -2.5% | -2.1% | -3.6% | 0.6× |
| Q2 FY09 | 23 Oct 2008 | -8.0% | +5.4% | -9.8% | 0.9× |
| Q1 FY09 | 1 Aug 2008 | +6.8% | +36.5% | +14.7% | 5.4× |
| Average | -0.1% | +0.1% | +0.8% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY—
Profit YoY—
Interest cost YoY—
Revenue QoQ+10.6%
Profit QoQ+2.9%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen2,905.00
Day range2,899.60 – 2,987.90
52-week range1,733.00 – 3,127.80
From 52w high-6.2%
RSI (14)54.9
ATR (14)146.46
Volume14.2K
Avg volume (20D)41.3K
Rel volume0.34×
Volatility (1Y)39.0%
Turnover₹4.2Cr
SMA 50 / 2002,758.34 / 2,333.96
Delivery percentage
Latest · 6 Oct 202645.9%
20-day avg43.3%
1-year avg52.1%
Percentile (own history)47th
Range3.4–94.6%
Sessions1,731
Over the last 20 sessions RPGLIFE settled 43.3% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 52.1%, so recent sessions are running 8.8 points lower than usual. The latest session ranks higher than 47% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +1.27% | -0.74% | +10.59% | +20.20% | +52.68% | +27.24% |
Valuation
CSVMarket cap₹4,851 Cr
P/E (TTM)—
EPS (TTM)—
Shares outstanding1.65Cr
Listed10 Jun 2008
Ownership
CSVPromoter72.95%
Promoter Δ QoQ0.00 pp
Public27.05%
FII0.95%
DII8.67%
Pledged0.00%
Quarterly results · consolidated
CSV| Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|
| Revenue (₹ Cr) | 180.0 | 176.9 | 195.7 |
| YoY chg | — | — | — |
| Net profit (₹ Cr) | 22.1 | 29.9 | 30.8 |
| YoY chg | — | — | — |
| Net margin | 12.3% | 16.9% | 15.7% |
| EPS | 13.38 | 18.08 | 18.60 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 72.95% · public 27.05%2021-092026-06
- Promoter
- Public and others
- Promoter
- 72.95%
- Public
- 27.05%
- Promoter change
- 0.00 pp
- Filed
- 20 Jul 2026
- FII
- 0.95%
- DII
- 8.67%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|
| Revenue from operations | 180.0 | 176.9 | 195.7 | |
| Other income | 3.4 | 12.4 | 4.7 | |
| Total income | 183.4 | 189.3 | 200.4 | |
| Total expenses | 145.9 | 150.2 | 158.9 | |
| └ Finance costs | 0.3 | 0.4 | 0.6 | |
| └ Depreciation | 5.4 | 5.7 | 5.9 | |
| Profit before tax | 29.1 | 40.2 | 41.5 | |
| Tax expense | 7.0 | 10.3 | 10.7 | |
| Net profit | 22.1 | 29.9 | 30.8 | |
| EPS | 13.38 | 18.08 | 18.60 | |
| Net margin | 12.29% | 16.90% | 15.72% | |
| PBT margin | 16.18% | 22.73% | 21.19% | |
| Tax rate | 24.00% | 25.62% | 25.81% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 28 Jul 2026.
3 quarters on file; a year-on-year comparison needs five.
RPGLIFE at a glance
- RPGLIFE closed at ₹2,933.2 on 6 Oct 2026, +1.27% on the day, +27.2% over one year, 6.2% below its 52-week high of ₹3,127.8.
- Delivery was 45.9% of traded quantity on 6 Oct 2026, the 47th percentile of its own 1,731 sessions with a reading (20-session average 43.3%, 1-year average 52.1%).
- Market capitalisation is ₹4,851 crore, with no positive trailing earnings for a P/E.
- Q1 FY27 results (consolidated, filed 28 Jul 2026): revenue ₹196 crore, net profit ₹31 crore; the price moved -1.3% on the first session after.
- Promoters held 72.95% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 17 Oct 2026 and 7 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE105J01010
SeriesEQ
Listed10 Jun 2008
History from10 Jun 2008
Sessions4,534
Turnover rank#964
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE